Loughborough University
Leicestershire, UK
LE11 3TU
+44 (0)1509 263171
Loughborough University

Loughborough University Institutional Repository

Please use this identifier to cite or link to this item: https://dspace.lboro.ac.uk/2134/27683

Title: The Lancet Gastroenterology & Hepatology Journal Cover August 1st 2017
Authors: Selby, Andrew
Keywords: Lancet
Gastroenterology
Hepatology
Issue Date: 2017
Publisher: Elsevier
Citation: SELBY, A., 2017. The Lancet Gastroenterology & Hepatology Journal Cover August 1st 2017. The Lancet Gastroenterology & Hepatology Journal, 2(8).
Abstract: Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial In the C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4–5 chronic kidney disease resulted in a high rate of virological cure compared with placebo. Here, we report sustained virological response (SVR), safety data, health-related quality-of-life (HRQOL), and virological resistance analyses in patients in C-SURFER who received immediate antiviral therapy or who received placebo before therapy.
Description: This paper is in closed access until Aug. 1st 2019.
Sponsor: Dr Robert Brierley, Dr Heather Van Epps
Version: Published
URI: https://dspace.lboro.ac.uk/2134/27683
Publisher Link: http://www.thelancet.com/journals/langas/issue/vol2no8/PIIS2468-1253(17)X0007-1
Appears in Collections:Closed Access (Arts)

Files associated with this item:

File Description SizeFormat
Selby_Lancet_CGH_Aug05_CMYK.pdfPublished version141.65 kBAdobe PDFView/Open

 

SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.